Ever since the artificial intelligence (AI) revolution took off, Nvidia (NASDAQ:NVDA) has been at the forefront, influencing various industries. Companies eager to stay ahead in the AI-driven era are seeking collaborations with the chip giant. One such company making waves in AI-powered healthcare analytics is Iqvia Holdings (NYSE:IQV).

What Does Iqvia Holdings Do?

Founded in 2016, Iqvia Holdings specializes in advanced analytics, technology solutions, and clinical research services tailored to the life sciences industry. As technology advances, so does Iqvia’s revenue. From $5.4 billion in 2014, it soared to $15.4 billion by 2024.

In the most recent fourth quarter, total revenue grew 2.3% to $3.9 billion, while full-year revenue rose 2.8% to $15.4 billion. Adjusted earnings per share (EPS) increased 9.9% in Q4 to $3.12, with a 9.1% annual increase to $11.13. The company also boasts a $31.1 billion backlog, with $7.9 billion expected to convert into revenue within a year.

Iqvia’s financial strength is further demonstrated by its $721 million in Q4 free cash flow, totaling $2.1 billion for the year. This enabled the company to repurchase $1.35 billion in shares while reducing its $13.9 billion debt.

How Iqvia and Nvidia Are Powering Healthcare with AI

On Jan. 13, Iqvia Holdings announced a strategic partnership with Nvidia to leverage cutting-edge AI technologies. Through Nvidia’s AI Foundry platform and Iqvia’s Connected Intelligence solutions, the company aims to automate complex workflows and accelerate AI-driven solutions in healthcare.

Why AI Adoption is Key in Healthcare Analytics

The healthcare and life sciences industries generate massive amounts of data. With AI-powered healthcare analytics, companies like Iqvia can process vast datasets faster and more efficiently. Nvidia’s advanced AI capabilities will enable Iqvia to:

Develop AI agents for healthcare applications

Utilize NVIDIA NIM microservices for real-time analytics

Leverage NVIDIA NeMo for generative AI solutions

Gain access to NVIDIA DGX Cloud for high-performance computing

By integrating Nvidia’s AI tools, Iqvia is positioning itself as a leader in AI-powered healthcare analytics. This collaboration could provide a significant competitive edge in an industry poised for rapid transformation.

What’s Next for Iqvia?

With this partnership, Iqvia expects full-year 2025 revenue to grow between 4% and 7%, reaching $15.7 billion to $16.1 billion. EPS is projected to rise between 5% and 9%, landing between $11.70 and $12.10. Analysts anticipate continued growth, with revenue increasing by 3.4% in 2025 and 6.07% in 2026, while earnings could rise by 6.9% and 11.2%, respectively.

At 16 times forward earnings and two times forward sales, Iqvia stock remains an attractive AI-driven healthcare play.

What Do Analysts Think About IQV Stock?

Wall Street analysts overwhelmingly favor Iqvia, with 17 out of 22 rating it a “Strong Buy.” The stock’s average price target of $246.96 suggests a potential 26% upside from current levels, with a high target of $270 indicating a possible 37.7% gain in the next 12 months.

As AI-powered healthcare analytics continues to evolve, Iqvia’s partnership with Nvidia could be the catalyst that propels the company to new heights. Investors looking for a strong AI-driven healthcare stock should keep an eye on Iqvia Holdings (NYSE:IQV).

Beyond its AI advancements, Iqvia Holdings is also expanding its global footprint by investing in new healthcare data infrastructure. The company is exploring additional collaborations with biotech firms and research institutions to further enhance AI-driven analytics. With an increasing demand for AI-powered solutions in medical research and patient care, Iqvia Holdings is well-positioned to capitalize on this trend. Over the next few years, we may see Iqvia integrating AI even deeper into clinical trials, drug discovery, and personalized medicine. As AI reshapes the healthcare landscape, Iqvia’s commitment to innovation makes it a compelling stock to watch.

Iqvia’s strategic moves suggest a long-term growth trajectory driven by AI integration. With regulatory agencies increasingly relying on AI-powered insights for drug approvals and patient outcomes, Iqvia stands to benefit from these evolving industry dynamics. The company’s ability to adapt and scale AI solutions efficiently could solidify its position as a leader in healthcare analytics, making it an attractive option for investors seeking exposure to AI-driven healthcare advancements.

Featured Image: DepositPhotos @ SergeyNivens

Disclaimer